Covid-19

Empresas de capital riesgo invierten en el negocio de los ensayos clínicos de medicamentos. ¿Cuál es el riesgo para los pacientes?

Para lanzar un nuevo fármaco al mercado, la Administración de Alimentos y Medicamentos (FDA) exige a las farmacéuticas estudios exhaustivos para demostrar su seguridad y eficacia. Conseguir que un medicamento salga al mercado unos meses antes, y con menos gastos de lo habitual, puede traducirse en beneficios millonarios para el fabricante.

KHN’s ‘What the Health?’: Medicaid Machinations

The lame-duck Congress has returned to Washington with a long health care to-do list and only a little time. Meanwhile, some of the states that have not yet expanded Medicaid eligibility under the Affordable Care Act are rethinking those decisions. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these topics and more. Also this week, Rovner interviews KHN’s Fred Clasen-Kelly, who reported and wrote the latest KHN-NPR “Bill of the Month” feature, about a mysterious mishap during minor surgery.

Mistrust and Polarization Steer Rural Governments to Reject Federal Public Health Funding

As the covid-19 pandemic grinds on, Elko County, Nevada, still lacks a public health department. Yet its elected leaders rejected federal funds that could have helped it create one. Decisions like the one in Elko, and ones made by officials with other state and local governments, leave health experts concerned about whether the country’s public health infrastructure will be prepared to handle future health challenges.

KHN’s ‘What the Health?’: The Midterm Shake-Up

Can’t see the audio player? Click here to listen on Acast. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts, or wherever you listen to podcasts. Click here for a transcript of the episode. The predicted Republican “red wave” was a no-show in this week’s midterm elections, but the margins in both the […]